<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="376">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04438980</url>
  </required_header>
  <id_info>
    <org_study_id>CORTIVID</org_study_id>
    <nct_id>NCT04438980</nct_id>
  </id_info>
  <brief_title>Glucocorticoids in COVID-19 (CORTIVID)</brief_title>
  <acronym>CORTIVID</acronym>
  <official_title>Treatment of COVID-19 Pneumonia With Glucocorticoids. A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Miguel Servet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Complejo Hospitalario de Navarra</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Sant Joan Despí Moisès Broggi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion Miguel Servet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Around 30% of admitted patients with COVID-19 pneumonia develop a hyper-inflammatory state
      whose progression to an acute respiratory distress syndrome (ARSD) could be prevented by the
      early initiation of immune-modulatory agents. The role of glucocorticoids (GC) in this
      setting remains controversial. This study aims to assess the safety and effectiveness of GC
      pulses to improve the clinical outcomes of patients with COVID-19 pneumonia with risen
      inflammatory biomarkers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients developing treatment failure</measure>
    <time_frame>At 14 days after randomization</time_frame>
    <description>• Death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients developing treatment failure</measure>
    <time_frame>At 14 days after randomization</time_frame>
    <description>• Need for admission in an intensive care unit (ICU)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients developing treatment failure</measure>
    <time_frame>At 14 days after randomization</time_frame>
    <description>• Need for mechanical ventilation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients developing treatment failure</measure>
    <time_frame>At 14 days after randomization</time_frame>
    <description>• Decrease in SpO2 &lt;90% (in ambient air) or PaO2 &lt;60 mmHg (in ambient air) or PaO2FiO2 &lt;300 mmHg, associated with radiological impairment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality at day 28</measure>
    <time_frame>At 28 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients requiring ICU admission</measure>
    <time_frame>At 28 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients requiring rescue-therapy with tocilizumab</measure>
    <time_frame>At 14 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>At 28 days after randomization</time_frame>
    <description>Time in days from randomization until the date of hospital discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of severe adverse events</measure>
    <time_frame>At 28 days after randomization</time_frame>
    <description>Any undesirable experience related to the use of the studied drugs, which causes patient's death, life-threatening risk, hospitalization or extension of a previous hospitalization, disability or permanent damage, requires intervention to prevent permanent impairment or damage, or is considered medically relevant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of bacterial, fungal or opportunistic infections</measure>
    <time_frame>At 28 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of inflammatory biomarkers related to COVID-19</measure>
    <time_frame>At 14 days after randomization</time_frame>
    <description>Change in plasma levels of C-reactive protein (CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of inflammatory biomarkers related to COVID-19</measure>
    <time_frame>At 14 days after randomization</time_frame>
    <description>Change in plasma levels of ferritin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of inflammatory biomarkers related to COVID-19</measure>
    <time_frame>At 14 days after randomization</time_frame>
    <description>Change in plasma levels of interleukin-6 (IL-6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of inflammatory biomarkers related to COVID-19</measure>
    <time_frame>At 14 days after randomization</time_frame>
    <description>Change in plasma levels of lactate dehydrogenase (LDH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of inflammatory biomarkers related to COVID-19</measure>
    <time_frame>At 14 days after randomization</time_frame>
    <description>Change in plasma levels of D-dimer (DD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of SARS-CoV-2 clearance.</measure>
    <time_frame>At 7 days after randomization</time_frame>
    <description>Negativization of RT-PCR for SARS-CoV-2 on nasopharyngeal swab or sputum</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Covid-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>Methylprednisolone Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care plus Methylprednisolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard of care plus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>-A dose of 120 mg/day of methylprednisolone for 3 days, administered by intravenous infusión</description>
    <arm_group_label>Methylprednisolone Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>-An infusion bag of 100 mL of 0.9% saline</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years old.

          -  Diagnosis of SARS-CoV-2 pneumonia confirmed by reverse transcriptase polymerase chain
             reaction (RT-PCR) on nasopharyngeal swab or sputum according to the recommendations of
             the Spanish Ministry of Health.

          -  Length of symptoms consistent with COVID-19 ≥7 days.

          -  Hospital admission.

          -  At least one of the following: CRP &gt;60 mg/L, IL-6 &gt;40 pg/mL, ferritin &gt;1000 μg/L.

          -  Acceptation of informed consent

        Exclusion Criteria:

          -  Allergy or contraindication to any of the drugs under study.

          -  SpO2 &lt;90% (in air ambient) or PaO2 &lt;60 mmHg (in ambient air) or PaO2/FiO2 &lt;300 mmHg.

          -  Ongoing treatment with glucocorticoids, immunosuppressive, or biologic drugs with
             another indication.

          -  Decompensated diabetes mellitus.

          -  Uncontrolled hypertension.

          -  Psychotic or manic disorder.

          -  Active cancer.

          -  Pregnancy or lactation.

          -  Clinical or biochemical suspicion (procalcitonin &gt;0.5 ng/mL) of active infection other
             than SARS-CoV-2.

          -  Out-of-hospital management patient.

          -  Conservative or palliative management patient.

          -  Participation in another clinical trial.

          -  Any important and uncontrolled medical, psychological, psychiatric, geographic or
             social problem that contraindicates the patient's participation in the trial or that
             does not allow adequate follow-up and adherence to the protocol and evaluation of the
             study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iñigo Les Bujanda, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario de Navarra</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Iñigo Les Bujanda, PhD</last_name>
    <phone>0034636346833</phone>
    <email>ilesbujanda@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ruth Garcia Rey, MS</last_name>
    <phone>0034848422163</phone>
    <email>ruth.garcia.rey@navarra.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Sant Joan Despí Moisès Broggi</name>
      <address>
        <city>Sant Joan Despí</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Loureiro Amigo, MD</last_name>
      <email>Jose.LoureiroAmigo@sanitatintegral.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iñigo Les Bujanda, PhD</last_name>
      <phone>0034636346833</phone>
      <email>ilesbujanda@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 18, 2020</study_first_submitted>
  <study_first_submitted_qc>June 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2020</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Covid-19</keyword>
  <keyword>pneumonia</keyword>
  <keyword>Inflammatory phase</keyword>
  <keyword>Glucocorticoids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected IPD will be available for exploitation in future research projects. This statement also includes the availability of the study protocol, the statistical analysis plan, the informed consent form, the clinical study report and the analytic code.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

